Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin

Neuro-Oncology

Volumn 16, Issue 10, 2014, Pages 1324-1332

  Deuis, Jennifer R ^a   Lim, Yu Ling ^a   De Sousa, Silmara Rodrigues ^a   Lewis, Richard J ^a   Alewood, Paul F ^a   Cabot, Peter J ^a   Vetter, Irina ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Analgesia; Chemotherapy induced neuropathy; Cisplatin; Nav1.6; Oxaliplatin

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; CALCIUM ION; CISPLATIN; FENTANYL; GABAPENTIN; LAMOTRIGINE; MAGNESIUM ION; MEXILETINE; OXALIPLATIN; OXCARBAZEPINE; PHENYTOIN; RETIGABINE; SODIUM CHANNEL NAV1.6; TOPIRAMATE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; SCN8A PROTEIN, MOUSE;

ADVERSE OUTCOME; ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; MALE; MOUSE; NEUROPATHY; NONHUMAN; POLYNEUROPATHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; HYPERALGESIA; METABOLISM; POLYNEUROPATHIES;

ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; MALE; MICE; MICE, INBRED C57BL; NAV1.6 VOLTAGE-GATED SODIUM CHANNEL; ORGANOPLATINUM COMPOUNDS; POLYNEUROPATHIES;

EID: 84924620696     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou048     Document Type: Article

References (49)

1. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007;130(Pt 4):1076-1088.
2. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, et al. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain. 1993;116(Pt 5):1017-1041.
3. Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984;54(7):1269-1275.
4. Roelofs RI, HrusheskyW, Rogin J, et al. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34(7):934-938.
5. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98(1-2):195-203.
6. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992;10(5):795-803.
7. Hovestadt A, van der Burg ME, Verbiest HB, et al. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol. 1992;239(3):143-146.
8. Leonard GD, Wright MA, Quinn MG, et al. Survey of oxaliplatinassociated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5(16).
9. Pasetto LM, D'Andrea MR, Rossi E, et al. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006;59(2):159-168.
10. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144(3):245-252.
11. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438-444.
12. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na (V) 1.6-resurgent and persistent current. Proc Natl Acad Sci USA. 2012;109(17):6704-6709.
13. Deuis JR, Zimmermann K, Romanovsky AA, et al. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain. 2013;154(9):1749-1757.
14. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res. 2006;12(15):4481-4484.
15. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009;132(Pt 10):2712-2723.
16. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother. 2005;39(1):128-135.
17. Nielsen KJ, Watson M, Adams DJ, et al. Solution structure of mu-conotoxin PIIIA, a preferential inhibitor of persistent tetrodotoxin-sensitive sodium channels. J Biol Chem. 2002;277(30):27247-27255.
18. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(4):382-390.
19. Laughlin TM, Tram KV, Wilcox GL, et al. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther. 2002;302(3):1168-1175.
20. Minami K, Hasegawa M, Ito H, et al. Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci. 2009;111(1):60-72.
21. Sakaue A, Honda M, Tanabe M, et al. Antinociceptive effects of sodium channel-blocking agents on acute pain in mice. J Pharmacol Sci. 2004;95(2):181-188.
22. Wieczorkiewicz-Plaza A, Plaza P, Maciejewski R, et al. Effect of topiramate on mechanical allodynia in neuropathic pain model in rats. Pol J Pharmacol. 2004;56(2):275-278.
23. Zimmermann K, Deuis JR, Inserra MC, et al. Analgesic treatment of ciguatoxin-induced cold allodynia. Pain. 2013;154(10):1999-2006.
24. Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2011; (2): CD005228.
25. Park HJ, Stokes JA, Pirie E, et al. Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept. Anesth Analg. 2013;116(1):224-231.
26. Ta LE, Low PA, Windebank AJ. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain. 2009;5(9).
27. Liu JJ, Kim Y, Yan F, et al. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem Pharmacol. 2013;85(2):207-215.
28. Sprowl JA, Ciarimboli G, Lancaster CS, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA. 2013;110(27):11199-11204.
29. Jong NN, Nakanishi T, Liu JJ, et al. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 2011;338(2):537-547.
30. Lancaster CS, Sprowl JA, Walker AL, et al. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther. 2013;12(8):1537-1544.
31. Caldwell JH, Schaller KL, Lasher RS, et al. Sodium channel Na (v) 1.6 is localized at nodes of ranvier, dendrites, and synapses. Proc Natl Acad Sci USA. 2000;97(10):5616-5620.
32. Fukuoka T, Kobayashi K, Yamanaka H, et al. Comparative study of the distribution of the alpha-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons. J Comp Neurol. 2008;510(2):188-206.
33. Xie W, Strong JA, Ye L, et al. Knockdown of sodium channel NaV1.6 blocks mechanical pain and abnormal bursting activity of afferent neurons in inflamed sensory ganglia. Pain. 2013;154(8):1170-1180.
34. Ren YS, Qian NS, Tang Y, et al. Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes. Brain Res Bull. 2012;87(2-3):244-249.
35. Jamieson SM, Liu J, Connor B, et al. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol. 2005;56(4):391-399.
36. Ta LE, Espeset L, Podratz J, et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27(6):992-1002.
37. Scott RH, Manikon MI, Andrews PL. Actions of cisplatin on the electrophysiological properties of cultured dorsal root ganglion neurones from neonatal rats. Naunyn Schmiedebergs Arch Pharmacol. 1994;349(3):287-294.
38. Renn CL, Carozzi VA, Rhee P, et al. Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain. 2011;7(29).
39. Tredici G, Tredici S, Fabbrica D, et al. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J Neurooncol. 1998;36(1):31-40.
40. Sittl R, Carr RW, Fleckenstein J, et al. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. Neurotoxicology. 2010;31(6):694-700.
41. Grunze H, von Wegerer J, Greene RW, et al. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology. 1998;38(3):131-138.
42. Pisciotta M, Prestipino G. Anticonvulsant phenytoin affects voltagegated potassium currents in cerebellar granule cells. Brain Res. 2002;941(1-2):53-61.
43. Wickenden AD, Yu W, Zou A, et al. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000;58(3):591-600.
44. Burgess DL, Kohrman DC, Galt J, et al. Mutation of a new sodium channel gene, Scn8a, in the mouse mutant 'motor endplate disease'. Nat Genet. 1995;10(4):461-465.
45. Craner MJ, Hains BC, Lo AC, et al. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain. 2004;127(Pt 2):294-303.
46. Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na (+)-Ca2+ exchanger. J Neurosci. 1992;12(2):430-439.
47. Xu XT, Dai ZH, Xu Q, et al. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatininduced sensory neuropathy in gastrointestinal cancers. J Dig Dis. 2013;14(6):288-298.
48. Wen F, Zhou Y, Wang W, et al. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Ann Oncol. 2013;24(1):171-178.
49. Frankenhaeuser B, Hodgkin AL. The action of calcium on the electrical properties of squid axons. J Physiol. 1957;137(2):218-244.